Aimei Health Technology (AFJK): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns Aimei Health Technology?
Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: First Trust Capital Management (13G/A filed Aug 10, 2026) and Glazer Capital (13G filed Feb 14, 2025). Mizuho Securities Usa Llc is listed on Form 4 filings as an owner of more than 10%. As of Jun 30, 2026, the largest holders reported on Form 13F were First Trust Capital Management (680,000 shares), Glazer Capital (133,744 shares) and Clear Street Group (83,337 shares).
Which institutions hold the most Aimei Health Technology shares?
Per Form 13F filings as of Jun 30, 2026:
- 1. First Trust Capital Management: 680,000 shares
- 2. Glazer Capital: 133,744 shares
- 3. Clear Street Group: 83,337 shares
- 4. Karpus Management: 77,125 shares
- 5. SBI Securities: 112 shares
- 6. UBS Group: 59 shares
- 7. Morgan Stanley: 43 shares
Sources:13G/A by First Trust Capital Management (Aug 10, 2026) ↗13G by Glazer Capital (Feb 14, 2025) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Largest holders of AFJK (all 13F filers)
- First Trust Capital Management680 KType not verified · 21.48% of the companyno data
- Glazer Capital134 KType not verified · 4.22% of the companyno data
- Clear Street Group83 KBank or trading desk · 2.63% of the companyno data
- Karpus Management77 KType not verified · 2.44% of the companyno data
- SBI Securities112Type not verified · 0.00% of the company+112
- UBS Group59Bank or trading desk · 0.00% of the company+45
- Morgan Stanley43Bank or trading desk · 0.00% of the company−7
- Shares
- 680 K
- Change
- no data
- % of the company
- 21.48%
See more
- Type
- Type not verified
- Value
- $7.7M
- Shares
- 134 K
- Change
- no data
- % of the company
- 4.22%
See more
- Type
- Type not verified
- Value
- $1.5M
- Shares
- 83 K
- Change
- no data
- % of the company
- 2.63%
See more
- Type
- Bank or trading desk
- Value
- $948K
- Shares
- 77 K
- Change
- no data
- % of the company
- 2.44%
See more
- Type
- Type not verified
- Value
- $888K
- Shares
- 112
- Change
- +112
- % of the company
- 0.00%
See more
- Type
- Type not verified
- Value
- $3.4K
- Shares
- 59
- Change
- +45
- % of the company
- 0.00%
See more
- Type
- Bank or trading desk
- Value
- $1.8K
- Shares
- 43
- Change
- −7
- % of the company
- 0.00%
See more
- Type
- Bank or trading desk
- Value
- $1.3K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Fundamentals
12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.
- Operating margin
- —
- Net margin
- —
- ROE
- —
- Revenue (TTM)
- —
- Revenue growth
- —
- Net income (TTM)
- $412K
- Net debt / EBITDA
- —
- Free cash flow (TTM)
- —
- Quality vs sector
- —
This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.
Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated
Earnings quality and debt
254.0% of net income does not come from operations.
- Operating cash flow ÷ net income (12 months)
- -0.90
- Interest coverage (operating income ÷ interest)
- no data
- Debt due within 12 months
- $2.2M1,497.76 times cash and investments
From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.
Insiders (Form 4)
10% owners who bought (6 m): 0
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
- First Trust Capital Management21.48%13G · amendmentfiling ↗Event: Apr 30, 2026 · filed: Aug 10, 2026
- Berkley W Rfell below 5%13G · amendmentfiling ↗Event: Jun 30, 2026 · filed: Aug 5, 2026
- Mizuho Financial Groupfell below 5%13G · amendmentfiling ↗Event: Dec 31, 2025 · filed: Feb 12, 2026
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
Flagged material events (8-K)
Notice of delisting or failure to meet a listing rule (Item 3.01)
Notice of delisting or failure to meet a listing rule (Item 3.01)
«Aimei Health Technology Co., Ltd Receives Nasdaq Notice Regarding Delayed Quarterly Report»
Notice of delisting or failure to meet a listing rule (Item 3.01)
«Aimei Health Technology Co., Ltd Receives Nasdaq Notice Regarding Delayed Annual Report»
Change in directors or officers (Item 5.02)
Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.
All material events (8-K)
Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.